Imbruvica (ibrutinib)

News alerts, weekly reports and conference planners

Company:

AbbVie, J&J

Drug class:

BTK inhibitor

Related drugs:

‹

›

No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	ibrutinib + rituximab Sensitive: A1 - Approval ibrutinib + rituximab Sensitive : A1	ibrutinib + rituximab Sensitive: A1 - Approval ibrutinib + rituximab Sensitive : A1
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	ibrutinib + rituximab Sensitive: A1 - Approval ibrutinib + rituximab Sensitive : A1	ibrutinib + rituximab Sensitive: A1 - Approval ibrutinib + rituximab Sensitive : A1
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	ibrutinib + obinutuzumab Sensitive: A1 - Approval ibrutinib + obinutuzumab Sensitive : A1	ibrutinib + obinutuzumab Sensitive: A1 - Approval ibrutinib + obinutuzumab Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	venetoclax + ibrutinib Sensitive: A1 - Approval venetoclax + ibrutinib Sensitive : A1	venetoclax + ibrutinib Sensitive: A1 - Approval venetoclax + ibrutinib Sensitive : A1
No biomarker	Small Lymphocytic Lymphoma	No biomarker	Small Lymphocytic Lymphoma	ibrutinib + rituximab Sensitive: A1 - Approval ibrutinib + rituximab Sensitive : A1	ibrutinib + rituximab Sensitive: A1 - Approval ibrutinib + rituximab Sensitive : A1
No biomarker	Small Lymphocytic Lymphoma	No biomarker	Small Lymphocytic Lymphoma	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	venetoclax + ibrutinib Sensitive: A1 - Approval venetoclax + ibrutinib Sensitive : A1	venetoclax + ibrutinib Sensitive: A1 - Approval venetoclax + ibrutinib Sensitive : A1
Chr del(11q)	Chronic Lymphocytic Leukemia	Chr del(11q)	Chronic Lymphocytic Leukemia	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	venetoclax + ibrutinib Sensitive: A2 - Guideline venetoclax + ibrutinib Sensitive : A2	venetoclax + ibrutinib Sensitive: A2 - Guideline venetoclax + ibrutinib Sensitive : A2
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2
TP53 mutation	Small Lymphocytic Lymphoma	TP53 mutation	Small Lymphocytic Lymphoma	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2
Chr del(17p)	Small Lymphocytic Lymphoma	Chr del(17p)	Small Lymphocytic Lymphoma	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2
TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	venetoclax + ibrutinib Sensitive: A2 - Guideline venetoclax + ibrutinib Sensitive : A2	venetoclax + ibrutinib Sensitive: A2 - Guideline venetoclax + ibrutinib Sensitive : A2
IGH mutation	Chronic Lymphocytic Leukemia	IGH mutation	Chronic Lymphocytic Leukemia	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	ibrutinib + rituximab + lenalidomide Sensitive: A2 - Guideline ibrutinib + rituximab + lenalidomide Sensitive : A2	ibrutinib + rituximab + lenalidomide Sensitive: A2 - Guideline ibrutinib + rituximab + lenalidomide Sensitive : A2
No biomarker	Hairy Cell Leukemia	No biomarker	Hairy Cell Leukemia	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2
TP53 deletion	Chronic Lymphocytic Leukemia	TP53 deletion	Chronic Lymphocytic Leukemia	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	pembrolizumab + nivolumab + ibrutinib Sensitive: A2 - Guideline pembrolizumab + nivolumab + ibrutinib Sensitive : A2	pembrolizumab + nivolumab + ibrutinib Sensitive: A2 - Guideline pembrolizumab + nivolumab + ibrutinib Sensitive : A2
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	pembrolizumab + ibrutinib Sensitive: A2 - Guideline pembrolizumab + ibrutinib Sensitive : A2	pembrolizumab + ibrutinib Sensitive: A2 - Guideline pembrolizumab + ibrutinib Sensitive : A2
TP53 mutation	Small Lymphocytic Lymphoma	TP53 mutation	Small Lymphocytic Lymphoma	pembrolizumab + ibrutinib Sensitive: A2 - Guideline pembrolizumab + ibrutinib Sensitive : A2	pembrolizumab + ibrutinib Sensitive: A2 - Guideline pembrolizumab + ibrutinib Sensitive : A2
Chr del(17p)	Small Lymphocytic Lymphoma	Chr del(17p)	Small Lymphocytic Lymphoma	pembrolizumab + ibrutinib Sensitive: A2 - Guideline pembrolizumab + ibrutinib Sensitive : A2	pembrolizumab + ibrutinib Sensitive: A2 - Guideline pembrolizumab + ibrutinib Sensitive : A2
No biomarker	Small Lymphocytic Lymphoma	No biomarker	Small Lymphocytic Lymphoma	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2
TP53 deletion	Small Lymphocytic Lymphoma	TP53 deletion	Small Lymphocytic Lymphoma	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2
TP53 mutation	Small Lymphocytic Lymphoma	TP53 mutation	Small Lymphocytic Lymphoma	venetoclax + ibrutinib Sensitive: A2 - Guideline venetoclax + ibrutinib Sensitive : A2	venetoclax + ibrutinib Sensitive: A2 - Guideline venetoclax + ibrutinib Sensitive : A2

Imbruvica (ibrutinib)

Associations
(186)

Associations
(186)

Imbruvica (ibrutinib)

Associations(186)

Associations(186)

Associations
(186)

Associations
(186)